SU953984A3 - Способ получени производных эргопептина или их солей - Google Patents

Способ получени производных эргопептина или их солей Download PDF

Info

Publication number: SU953984A3
Authority: SU; USSR - Soviet Union
Prior art keywords: methyl; capsules; mixture; methylene chloride; tablets
Prior art date: 1979-06-12

Application number

SU802937551A

Other languages

English (en)

Russian (ru)

Inventor

Боллигер Георг

Штютц Петер

Original Assignee

Сандос Аг (Фирма)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-06-12

Filing date

1980-06-11

Publication date

1982-08-23

1979-06-12 Priority claimed from CH547679A external-priority patent/CH642082A5/de

1979-06-12 Priority claimed from CH547779A external-priority patent/CH643560A5/de

1980-06-11 Application filed by Сандос Аг (Фирма) filed Critical Сандос Аг (Фирма)

1982-08-23 Application granted granted Critical

1982-08-23 Publication of SU953984A3 publication Critical patent/SU953984A3/ru

Links

238000000034 method Methods 0.000 title claims description 4
150000003839 salts Chemical class 0.000 title description 2
239000000203 mixture Substances 0.000 claims description 8
150000001875 compounds Chemical class 0.000 claims description 6
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
239000002775 capsule Substances 0.000 claims description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
229920002472 Starch Polymers 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 3
239000013543 active substance Substances 0.000 claims description 3
230000000694 effects Effects 0.000 claims description 3
-1 polyoxyethylene stearate Polymers 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
235000019698 starch Nutrition 0.000 claims description 3
239000008107 starch Substances 0.000 claims description 3
239000000725 suspension Substances 0.000 claims description 3
239000000454 talc Substances 0.000 claims description 3
229910052623 talc Inorganic materials 0.000 claims description 3
108010010803 Gelatin Proteins 0.000 claims description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
235000021355 Stearic acid Nutrition 0.000 claims description 2
239000000654 additive Substances 0.000 claims description 2
229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
239000000969 carrier Substances 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
239000008273 gelatin Substances 0.000 claims description 2
229920000159 gelatin Polymers 0.000 claims description 2
235000019322 gelatine Nutrition 0.000 claims description 2
235000011852 gelatine desserts Nutrition 0.000 claims description 2
239000008101 lactose Substances 0.000 claims description 2
235000019359 magnesium stearate Nutrition 0.000 claims description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
239000003755 preservative agent Substances 0.000 claims description 2
239000008117 stearic acid Substances 0.000 claims description 2
239000006188 syrup Substances 0.000 claims description 2
235000020357 syrup Nutrition 0.000 claims description 2
235000012222 talc Nutrition 0.000 claims description 2
NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims 2
239000007787 solid Substances 0.000 claims 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
239000005995 Aluminium silicate Substances 0.000 claims 1
241000416162 Astragalus gummifer Species 0.000 claims 1
229920002261 Corn starch Polymers 0.000 claims 1
101100320345 Drosophila melanogaster yem gene Proteins 0.000 claims 1
241001331845 Equus asinus x caballus Species 0.000 claims 1
229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
229920001615 Tragacanth Polymers 0.000 claims 1
238000010521 absorption reaction Methods 0.000 claims 1
239000004480 active ingredient Substances 0.000 claims 1
235000012211 aluminium silicate Nutrition 0.000 claims 1
235000010216 calcium carbonate Nutrition 0.000 claims 1
239000001506 calcium phosphate Substances 0.000 claims 1
229910000389 calcium phosphate Inorganic materials 0.000 claims 1
235000011010 calcium phosphates Nutrition 0.000 claims 1
239000008120 corn starch Substances 0.000 claims 1
229960000807 dihydroergotamine mesylate Drugs 0.000 claims 1
235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims 1
239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims 1
210000001035 gastrointestinal tract Anatomy 0.000 claims 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims 1
235000010445 lecithin Nutrition 0.000 claims 1
239000000787 lecithin Substances 0.000 claims 1
229940067606 lecithin Drugs 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
229920000609 methyl cellulose Polymers 0.000 claims 1
239000001923 methylcellulose Substances 0.000 claims 1
229960002900 methylcellulose Drugs 0.000 claims 1
235000010981 methylcellulose Nutrition 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 claims 1
235000010413 sodium alginate Nutrition 0.000 claims 1
239000000661 sodium alginate Substances 0.000 claims 1
229940005550 sodium alginate Drugs 0.000 claims 1
239000000375 suspending agent Substances 0.000 claims 1
229940126585 therapeutic drug Drugs 0.000 claims 1
235000010487 tragacanth Nutrition 0.000 claims 1
239000000196 tragacanth Substances 0.000 claims 1
229940116362 tragacanth Drugs 0.000 claims 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
238000009736 wetting Methods 0.000 claims 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
238000002844 melting Methods 0.000 description 16
230000008018 melting Effects 0.000 description 16
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
238000002425 crystallisation Methods 0.000 description 15
230000008025 crystallization Effects 0.000 description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
230000006378 damage Effects 0.000 description 11
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
238000000354 decomposition reaction Methods 0.000 description 5
235000019439 ethyl acetate Nutrition 0.000 description 5
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
239000000243 solution Substances 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
229950001817 alpha-ergocryptine Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229960004704 dihydroergotamine Drugs 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
230000002792 vascular Effects 0.000 description 2
HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
VPSXHKGJZJCWLV-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(1-ethylpiperidin-4-yl)oxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OC1CCN(CC1)CC VPSXHKGJZJCWLV-UHFFFAOYSA-N 0.000 description 1
206010000599 Acromegaly Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000018152 Cerebral disease Diseases 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
208000003443 Unconsciousness Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229960004290 dihydroergocornine Drugs 0.000 description 1
229960004318 dihydroergocristine Drugs 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
229960004943 ergotamine Drugs 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000000155 melt Substances 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
TUNQTZDLMCRIIZ-UHFFFAOYSA-N pyrrolo[1,2-a]pyrazine hydrochloride Chemical compound Cl.C1=NC=CN2C=CC=C21 TUNQTZDLMCRIIZ-UHFFFAOYSA-N 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
208000009999 tuberous sclerosis Diseases 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SU802937551A 1979-06-12 1980-06-11 Способ получени производных эргопептина или их солей SU953984A3 (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH547679A CH642082A5 (en)	1979-06-12	1979-06-12	Ergopeptin derivatives, their preparation and use
CH547779A CH643560A5 (en)	1979-06-12	1979-06-12	Ergopeptin derivatives, their preparation and use

Publications (1)

Publication Number	Publication Date
SU953984A3 true SU953984A3 (ru)	1982-08-23

Family

ID=25697798

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SU802937551A SU953984A3 (ru)	1979-06-12	1980-06-11	Способ получени производных эргопептина или их солей

Country Status (3)

Country	Link
AT (1)	AT378534B (de)
CS (2)	CS221924B2 (de)
SU (1)	SU953984A3 (de)

1980
- 1980-06-11 CS CS413180A patent/CS221924B2/cs unknown
- 1980-06-11 SU SU802937551A patent/SU953984A3/ru active
- 1980-06-11 AT AT0306580A patent/AT378534B/de not_active IP Right Cessation
- 1980-06-11 CS CS945281A patent/CS221925B2/cs unknown

Also Published As

Publication number	Publication date
AT378534B (de)	1985-08-26
CS221924B2 (cs)	1983-04-29
CS221925B2 (cs)	1983-04-29
ATA306580A (de)	1985-01-15

Publication	Publication Date	Title
JP3145715B2 (ja)	2001-03-12	無水７−（［１α，５α，６α］−６−アミノ−３−アザビシクロ［３．１．０］ヘキサ−３−イル）−６−フルオロ−１−（２，４−ジフルオロフェニル）−１，４−ジヒドロ−４−オキソ−１，８−ナフチリディン−３−カルボン酸メタンスルホン酸塩の新規な結晶形態
EP0623621A1 (de)	1994-11-09	Oxazabicycloderivate und ihre Verwendung als 5-HT4 Rezeptor-Agonisten
US4594246A (en)	1986-06-10	Pharmaceutically-acceptable amine salts of 6-β-halopenicillanic acids
WO2002000629A9 (en)	2003-05-15	Iminopyrimidine nmda nr2b receptor antagonists
JP2003528874A (ja)	2003-09-30	カベルゴリンの結晶形ｉｉ
JP2003528873A (ja)	2003-09-30	カベルゴリン（ｃａｂｅｒｇｏｌｉｎｅ）の結晶性形態ＶＩＩ
JPH09510222A (ja)	1997-10-14	２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピン化合物の酸付加塩
JP3853389B2 (ja)	2006-12-06	新規の３−フェニルスルホニル−３，７−ジアザビシクロ［３，３，１］ノナン−化合物、その製法及び抗不整脈剤
EP1767536B1 (de)	2011-06-29	Chinolincarbonsäurederivate, deren herstellungsverfahren und pharmazeutische verwendung
WO2020141155A1 (en)	2020-07-09	Pantothenamide analogues
EP0765322B1 (de)	2001-07-25	Indolderivate als prodrugs von "5-ht1-like" rezeptor agonisten
CZ20021981A3 (cs)	2003-01-15	Heterocyklické deriváty
KR850000474B1 (ko)	1985-04-08	6β-[2-(2'-메틸페녹시카르보닐)-2-티엔-3'-일아세트아미도]페니실란산의 제조방법
RU2151152C1 (ru)	2000-06-20	Полиморфы 6-n-(l-ala-l-ala)-тровафлоксацина
JP2666320B2 (ja)	1997-10-22	抗菌化合物
FI83869B (fi)	1991-05-31	Foerfarande foer framstaellning av nya terapeutiskt anvaendbara ergolinderivat.
JP2002527442A (ja)	2002-08-27	心血管、抗腫瘍、抗感染症、および抗炎症の活性を有するイミダゾ−ベンゾアゼピン
HU184299B (en)	1984-07-30	Process for producing ergopeptine derivatives
CS221924B2 (cs)	1983-04-29	Způsob výroby ergopeptinových derivátů
JPH03197463A (ja)	1991-08-28	新規ベンズアゼピン
US5502209A (en)	1996-03-26	Benzopyrancarboxamide derivatives, salts thereof, process for the preparation of same and use thereof
JP2621204B2 (ja)	1997-06-18	抗菌化合物
JPH0820586A (ja)	1996-01-23	１−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
SU1022660A3 (ru)	1983-06-07	Способ получени производных эргопептина или их солей
HU187003B (en)	1985-10-28	Process for producing ergot-alkaloides